Skip to main content

Articles

Payers' Guide, FDA Approvals

Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma

Payers' Guide, FDA Approvals

Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults

Payers' Guide, FDA Approvals

Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis

Payers' Guide, FDA Approvals

Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma

Payers' Guide, FDA Approvals

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

A Payer’s Perspective on CDK4/6 Inhibitors

Breast Cancer, Oncology

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

A Pharmacist’s Perspective on CDK4/6 Inhibitors

Original Research

Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines

Bruce S. Pyenson, FSA, MAAA; Gabriela Dieguez, FSA, MAAA; Christine Ferro; Maushumi Mavinkurve, MPH; Yuri Sanchez Gonzalez, PhD

Stakeholder Perspective

Importance of Health Outcomes Research for the Treatment of Hepatitis C Infection

Jack E. Fincham, PhD, RPh

Page 75 of 244
Results 741 - 750 of 2439